According to Sino Biopharmaceutical, AstraZeneca will pay $200 million up front and a total of up to $1.9 billion for the development, manufacturing, and commercialization rights to Sino Biopharm’s TQC3721 inhaled PDE3/4 inhibitor outside of China. The deal includes milestones and royalties on potential sales of TQC3721 for the treatment of COPD as well as global rights to several other Sino Biopharm development programs, the company said.
Sino Biopharm says that a Phase 3 trial of a nebulized formulation of TQC3721 is underway, and a dry powder formulation is in Phase 2 development. The company already markets a budesonide inhalation suspension and a dry powder tiotropium formulation for inhalation.
On the same day that it announced the AstraZeneca deal, Sino Biopharm said that it has acquired mainland Chinese rights to GSK’s Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol DPI and Anoro Ellipta umeclidinium / vilanterol DPI. Trelegy Ellipta was approved in China for the treatment of COPD in 2019 and for the treatment of asthma earlier this year. Anoro Ellipta was approved in China for the treatment of COPD in 2018.
Read the Sino Biopharmaceutical press release on the AstraZeneca deal
Read the Sino Biopharmaceutical press release on the GSK deal
